Morgan Stanley Dermata Therapeutics, Inc. Transaction History

Morgan Stanley

  • $1.35 Trillion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$0.18 - $184.8 $101 - $103,857
562 New
562 $0
Q2 2022

Aug 15, 2022
SELL
$115.2 - $319.2 $345 - $957
-3 Closed
0 $0
Q1 2022

Oct 27, 2022
BUY
$223.2 - $571.2 $669 - $1,713
3 New
3 $0
Q1 2022

May 13, 2022
SELL
$223.2 - $571.2 $110,930 - $283,886
-497 Reduced 99.4%
3 $0
Q4 2021

Feb 14, 2022
BUY
$374.4 - $1500.0 $187,200 - $750,000
500 New
500 $1,000

Others Institutions Holding DRMA

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About Dermata Therapeutics, Inc.

DRMA Quotes by TradingView
  • Ticker DRMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 10,102,200
  • Market Cap $13.5M
  • Description
  • Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe ...
More about DRMA
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email